MedTrace Logo

Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation

NCT04939675 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-06-25

No results posted yet for this study

Summary

Atypical presentations in epilepsy may include confusion status, acute maniac or delirious condition, loss of cognitive ability such as speech, interaction skills, or other praxis. Current diagnosis of epilepsy did not address on definition of seizure. The new insights of seizure semiology and their treatment response, suggest the screen tool and diagnostic criteria of epilepsy can be revised.

In this study, we have two aims. The first aim is to develop a screening questionnaire by adding new semiology of epilepsy, including abnormality in psychiatry, cognition, and sleep, and to test its accuracy. The second aim is to evaluate the benefits in cognition of anti-epileptic drug intervention in participants with positive screening results.

Conditions

Interventions

DRUG

Zonisamide 100mg

Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily

DRUG

Levetiracetam 500mg

Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily

DRUG

LamoTRIgine 50mg

Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kai-Chieh Chang, M.D. · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-06-30
Completion
2025-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939675 on ClinicalTrials.gov